A-Raf kinase can inhibit apoptosis by binding to the pro-apoptotic MST2 kinase. This function relies on expression of hnRNP H, which ensures the correct splicing of a-raf mRNA needed to produce full-length A-Raf protein. Here we show that expression of hnRNP H and production of full-length A-Raf is positively controlled by c-Myc. Low c-Myc reduces hnRNP H expression and switches a-raf splicing to produce A-Rafshort, a truncated protein. Importantly, A-Rafshort fails to regulate MST2 but retains the Ras binding domain such that it functions as a dominant negative mutant suppressing Ras activation and transformation. Human colon and head and neck cancers exhibit high hnRNP H and high c-Myc levels resulting in enhanced A-Raf expression and reduced expression of ARafshort. Conversely, in normal cells and tissues where c-Myc and hnRNP H are low, A-Rafshort suppresses ERK activation such that it may act as a safeguard against oncogenic transformation. Our findings offer a new paradigm to understand how c-Myc coordinates diverse cell functions by directly affecting alternate splicing of key signaling compotents.
Introduction
The family of Raf protein kinases, which comprises A-Raf, B-Raf, and Raf-1, is at the apex of the three-tiered Raf-MEK-ERK/MAPK pathway that regulates many fundamental cellular functions, including proliferation, differentiation, transformation, apoptosis and metabolism (1) . Raf kinase activation is initiated by binding to activated Ras GTPases at the cell membrane, which triggers a complex series of activation events that comprise interactions with proteins and lipids as well as coordinated de-phosphorylation and phosphorylation events (2, 3) . A-Raf is the least studied member of the Raf kinase family (4) . In general, ARaf seems to be regulated similar to Raf-1, with binding to activated Ras initiating the growth factor induced activation of A-Raf. However, A-Raf is a poor MEK kinase with barely measurable catalytic activity, which is due to unique non-conserved amino acid substitutions in the N-region (5) . Independent of kinase activity, A-Raf constitutively binds mammalian sterile 20-like kinase (MST2) and suppresses MST2 activation and induced apoptosis (6) .
The ERK pathway is frequently activated in cancer, often due to activating mutations in Ras (7, 8) or B-Raf (9, 10) . By contrast, Raf-1 is rarely mutated (11) , and to date no oncogenic A-Raf mutations were found. However, elevated A-Raf expression levels have been observed in a number of malignancies including astrocytomas (12) , pancreatic ductal carcinoma (13) , angioimmunoblastic lymphadenopathies (14) , head and neck squamous cell carcinomas, and colon carcinomas (6, 15) .
One way to regulate protein expression and activity is alternative splicing. For B-Raf several different splice forms are known. Two variable exons, 8b and 10, allow for the generation of four distinct isoforms (16, 17) . While the presence of exon 10 enhances the basal kinase activity and affinity to MEK, exon 8b has the opposite effect (16) . Thyroid carcinomas express B-Raf splice variants that lack the N-terminal auto-inhibitory domain resulting in constitutively active B-Raf variants, suggesting that alternative splicing regulation is a pathophysiological mechanism for oncogenic B-Raf activation (18) . An alternative Raf-1 splice form lacking exon 3 was reported in lung cancer, however the functional consequences are unknown (19) . Recently, two alternative murine A-Raf splice forms were described, DA-Raf1 and DA-Raf2, which contain the Ras binding domain (RBD) but lack the kinase domain due to pre-terminal stop codons (20, 21) . DA-Raf1 and DA-Raf2 bind to activated Ras, but due to the lack of a kinase domain cannot transduce a signal and act as dominant-negative antagonists of the Ras-ERK pathway. Thus, DA-Raf1 is a positive regulator of myogenic differentiation by inhibiting activation of the ERK pathway (20) . In another cellular environment, DA-Raf2 binds and colocalizes with the ARF6 GTPase on tubular endosomes and acts as dominant negative effector of endocytic trafficking (21) . We recently reported that expression of the full length A-Raf protein requires the expression of the splice factor hnRNP H, which is upregulated in several tumours including colon and head and neck cancers (6, 15) We showed that hnRNP H upregulation ensures the expression of the mature a-raf mRNA thus allowing the sufficient production of full-length A-Raf protein to counteract MST2-mediated apoptosis.
Here, we report that hnRNP H is a direct transcriptional target of c-Myc, which stimulates its expression. The proto-oncogenic transcription factor c-Myc is a key regulator of various cellular processes such as cell growth, proliferation, apoptosis, and differentiation (22, 23) . Recent studies suggest that c-Myc regulates about 15% of all annotated genes by direct transcriptional activation (24, 25) . Deregulated and elevated expression of c-myc has been shown for a wide range of cancers and it is estimated that c-Myc is involved in 20% of all human cancers (26) . We show that hnRNP H maintains the expression of full-length A-Raf protein by suppressing alternative splicing of the a-raf mRNA. This novel splice form, ARaf short , incorporates intronic sequences, and generates a 171 amino acid protein, which lacks the kinase domain. While A-Raf short fails to regulate MST2-mediated apoptosis, it is a potent inhibitor of ERK signaling and cellular transformation by binding and blocking activated Ras. A-Raf short expression levels were reduced in several cancer entities, suggesting that A-Raf short acts like a tumour suppressor protein in these tumours.
Materials and Methods

Cell lines
HeLa, GHD-1, HCT116, and NIH3T3 cells were cultured in standard DMEM containing 10% fetal calf serum (FCS). Cell lines were either purchased from Cancer Research UK or ATCC and were authenticated by the European Collection of Cell Cultures (ECACC). GHD-1 is a self-established cell line from a hypopharynx HNSCC tumour (27) .
Transfections
Transient transfections were conducted with Lipofectamine 2000 reagent (Invitrogen, Paisley, UK) or the Nucleofector system (Lonza Cologne, Cologne, Germany) according to the manufacturers' instructions.
Focus Assays
Focus assays were conducted as described previously (28) . Briefly, NIH 3T3 cells were transfected with Lipofectamine (Invitrogen) and allowed to grow to confluence. The plates were incubated for 12-15 days. Then, cells were fixed, stained with Giemsa, and the foci were counted.
Semi-quantitative RT-PCR
RNA from human tissues was isolated using the Precellys 24 cell lysis system (Bertin Technologies, Montigny-le-Bretonneux, France). Total RNA from tissues and cell lines was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany and cDNA was generated using the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen, Paisley, UK) according to the manufacturers' instructions.
Immunoprecipitations
Immunoprecipitations were conducted as described previously (6) with the following immobilized antibodies: Monoclonal mouse anti-HA tag antibody 3F10 (Roche Diagnostics, Mannheim, Germany), monoclonal mouse anti-flag antibody M2 (Sigma, Taufkirchen, Germany), polyclonal goat anti-human MST2 antibody sc-6211 (Santa Cruz, Santa Cruz, US), monoclonal mouse anti-human Ras antibody sc-29 (Santa Cruz, Santa Cruz, US).
MST2-kinase activity assay
MST2 kinase activity was measured by in-gel assays as described before (29) .
Apoptosis assays
Apoptosis was determined as described previously (6) by measuring subgenomic DNA.
Statistical analysis
Significance levels were determined by two-tailed Student t-test analyses. Due to the nonnormal distribution of the expression analysis data (RT-PCR), results are given as the median with the interquartile range (IQR). For comparison of hnRNP H and A-Raf isoform expression between sample groups, we used the Wilcoxon signed-rank test. All tests were two-sided and results considered significant if p<0.05.
Results
HnRNP H regulates A-Raf isoform selection
We reported recently, that the splice factor hnRNP H is necessary for the proper expression of the mature A-Raf mRNA (6) . Here we show that, when hnRNP H is depleted a novel, alternatively spliced A-Raf mRNA species appears at the expense of the mature mRNA.
Depletion of hnRNP H decreased the levels of mature A-Raf mRNA and full-length protein levels, while causing the appearance of a new mRNA species, which yielded a larger PCR product (Fig. 1A) . Sequencing revealed that introns two and four of the a-raf gene were included while introns one and three were spliced out ( Figure S1 and S2 ). This alternative araf short mRNA encodes 171 amino acids that are only partially related to the A-Raf wt protein sequence due to the intronic inclusions. PANTHER database entries for the full-length generic and the alternative mRNAs/proteins are hCT20300/hCP44398 and hCT2257035/ hCP1885829, respectively. The cognate A-Raf short protein lacks the C-terminal two-thirds of A-Raf wt including the kinase domain because of the presence of a stop codon at nucleotide position 716 in intron 4 (Fig. S2) . Pre-terminated mRNAs are commonly prone to nonsense-mediated decay (32) . However, endogenous A-Raf short protein was detectable (Fig. 1B) suggesting a physiological function for A-Raf short . Furthermore, downregulation of hnRNP H caused a reduction in the expression of the full length A-Raf wt protein with a concomitant increase in the expression of the A-Raf short protein (Fig. 1B) , confirming the results of the mRNA expression at the protein level. Pre-incubation of primary antibodies with the A-Raf short peptide used for immunisation resulted in a complete loss of detection by the A-Raf short -, but not by the HA-specific antibody (Fig. 1C) .
Alternative splice variants of a-raf differ in function
Full-length A-Raf prevents apoptosis by sequestering and inactivating the proapoptotic kinase MST2 (6) . In contrast, A-Raf short did not interact with flag-tagged MST2 or endogenous MST2 (Figs. 2A,B) . Consequently, A-Raf short was neither able to suppress endogenous MST2 kinase activity (Fig. 2C ), nor apoptosis in response to hnRNP H knockdown, as measured by the percentage of cells with a subG1 DNA content, the cleavage of PARP and caspase 3 ( Fig. 2D) .
A-Raf short negatively regulates the Ras-ERK pathway
The truncated A-Raf short contains the Ras-binding domain (RBD) including novel amino acids derived from intronic sequences but lacks the S/T rich domain and the kinase domain. This structure suggested that A-Raf short might act as dominant-negative Ras antagonist. Overexpression of A-Raf short in HeLa, GHD-1, and HCT116 cancer cells (Fig. 3A) , reduced cell numbers (Fig. 3A) , possibly by inhibition of Ras-ERK signalling. In serum-stimulated HeLa cells overexpression of A-Raf short leads to a decrease in pERK levels 3-fold while having no effect in quiescent cells ( Fig. 3B-C, Fig. 4A ). In contrast, phosphorylation levels of Akt were unchanged after A-Raf short overexpression (Fig. 3C ) suggesting that A-Raf short selectively antagonizes Ras-ERK signalling leaving Ras-PI3K-Akt signalling unaffected. While increased expression of A-Raf short led to a decrease in ERK activity, depletion of ARaf short using an isoform-specific siRNA had the opposite effect, i.e. increasing activating phosphorylation levels of ERK (Fig. 3D) . In serum-stimulated HeLa cells, knockdown of ARaf short increased pERK by 30%, while having no effect in quiescent cells (Fig. 3D) .
A-Raf short interacts with Ras and antagonises Ras transformation
In order to act as a Ras antagonist, A-Raf short should interact with activated Ras. We Europe PMC Funders Author Manuscripts (Fig. 4A) . The same results were obtained with endogenous A-Raf short and Ras (Fig. 4B ).
Furthermore, experiments where different amounts of A-Raf short and A-Raf WT were cotransfected, showed that A-Raf short efficiently competes with A-Raf WT for binding to activated Ras (Fig. 4C ). These data confirm that A-Raf short acts as a physiological negative regulator of Ras-ERK signalling.
Oncogenic Ras is a well-described activator of Ras-mediated ERK signalling and induces transformation in mouse fibroblasts (33, 34) . As A-Raf short interacted with activated Ras, and abrogated ERK activation, we asked whether oncogenic Ras-induced transformation was inhibited by A-Raf short . NIH3T3 cells were transfected with activated Ras mutants (HRasV12, K-RasV12, N-RasV12) and co-transfected with A-Raf short and tested for the ability to generate foci of transformed cells (Fig. 4C,D) . A-Raf short significantly decreased foci numbers with all three Ras isoforms suggesting that A-Raf short can inhibit transformation by all three Ras members. In order to prove that A-Raf short is acting directly on Ras and not on downstream effectors, NIH3T3 cells were co-transfected with A-Raf short and the viral Raf oncogene (vRaf), which lacks the Ras binding domain and transforms cells independently of Ras (33) . A-Raf short had no significant effect on v-Raf induced foci numbers, showing that A-Raf short is inhibiting activated Ras and not the downstream kinase Raf (Fig. S3A, B) . We also tested whether the function of A-Raf short differs from other known A-Raf splicing isoforms. In colony formation assays, daRaf1 and daRaf2, like A-Raf short , significantly decreased foci numbers with all three Ras isoforms suggesting that these isoforms have overlapping functions (Fig. S3C, D ).
c-Myc regulates A-Raf isoform selection via hnRNP H
hnRNP H is over expressed in several carcinoma entities and regulates a-raf splicing (6). We asked therefore, which process is responsible for the expression of hnRNP H. As hnRNP H was found as a target gene of the proto-oncogene c-Myc in microarray experiments (24) we tested this hypothesis experimentally in more detail. Depleting c-Myc from HeLa cells using specific siRNAs reduced hnRNP H protein expression levels and, in parallel, decreased levels of A-Raf WT and increased levels of A-Raf short ( Figure 5A ). Increased cell confluence triggered a similar response, i.e. decreasing levels of c-Myc, hnRNP H, and A-Raf WT while increasing levels of A-Raf short (Fig. S4) . These results suggest that a concerted response of c-Myc, hnRNP H and A-Raf isoform expression is part of the physiological programme how cells respond to different growth conditions. To ascertain that this response was coordinated by c-Myc, we transfected HeLa cells with MycER T (35) . MycER T is a chimeric protein where c-Myc is fused to a mutated ligand binding domain of the human estrogen receptor. MycER T is retained in the cytoplasm due to the ER portion binding to Hsp90. Addition of the estrogen analog 4-hydroxytamoxifen (4-OHT) releases MycER T and triggers its translocation to the nucleus and activation of Myc-induced transcription. In the absence of 4-OHT, expression levels of hnRNP H, A-Raf WT , and A-Raf short were constant over a timecourse of 8 hrs. Upon addition of 4-OHT, hnRNP H and A-Raf WT levels increased, while A-Raf short expression decreased ( Figure 5B ). Additional knock-down of hnRNP H using specific siRNAs abrogated this effect indicating that c-Myc is regulating A-Raf isoform selection via control of hnRNP H expression. Endogenous activation of c-Myc by EGF stimulation corroborated these results ( Figure 5C ). While expression levels of hnRNPH, A-Raf WT , and A-Raf short remained stable in starved cells, activation of c-Myc led to increased hnRNP H and A-Raf WT expression, but decreased A-Raf short expression.
Data from the ENCODE project (31) suggested, that c-Myc binds to three regions in the HNRNPH1 promoter (Fig. S5) . We could identify four putative, non-canonical E-Boxes 957bp (CATGTG), 949bp (CACATG), 530bp (CAGCTG), and 63bp (CAGCTG) upstream of the transcription start site, which coincide with the ChIP-Chip data from ENCODE in six different cell lines (Fig. S5) . In order to determine direct interaction of c-Myc with the HNRNPH1gene we performed a chromatin immunoprecipitation (ChIP) analysis of the human HNRNPH1 promoter. ChIP indicated that c-Myc was constitutively present at three E-Boxes of the HNRNPH1 promoter region (957bp, 949bp, 530bp) in both serum-starved and stimulated cells. However, c-Myc was recruited to the E-box nearest to the transcription start site only in stimulated cells (Fig. 5D) . Collectively, our results show that hnRNP H is a direct target of the proto-oncogene c-Myc and that c-Myc regulates the ERK pathway via hnRNP H and subsequent regulation of A-Raf isoform expression.
The A-Raf short isoform is downregulated in carcinomas
The expression of the proto-oncogene c-Myc is elevated in a plethora of human tumours (22) . Additionally, hnRNPH and A-Raf WT were shown to be overexpressed in several carcinoma entities including head and neck carcinomas and colon carcinomas (6) . Therefore, we asked if A-Raf short and other A-Raf isoforms are regulated during carcinogenesis and whether their expression is dependent on the expression of the upstream regulators c-Myc and hnRNP H. To this end, endogenous mRNA expression levels of c-myc, hnrnph, a-raf wt , and a-raf short were analysed in a series of human head and neck carcinomas (T, n=17) and adjacent non-malignant tissues (N, n=14) by semi-quantitative RT-PCR (Fig. 6A) . At the single-patient level, a median relative expression of 2.3-fold for c-myc, 1.7-fold for hnrnph, 1.5-fold for a-raf wt , and 0.5-fold for a-raf short in tumour specimens was calculated, indicating that c-myc, hnrnph and a-raf wt are over expressed in carcinomas. In contrast, araf short appears to be downregulated in tumours.
Additionally, after stratifying patients according to their relative expression levels of c-myc, hnRNP H, a-raf wt , and a-raf short mRNA in tumour tissue, a significant number of patients showed high expression of c-myc ( 2 =7.0, p=0.082), hnRNP H ( 2 =17.3, p=0.0001) and araf wt ( 2 =24.1, p=0.0001) in tumours while at the same time showing a significant downregulation of a-raf short ( 2 =7.0, p=0.008).
Comparing the relative expression in normal and tumour tissues (Fig. 6B , Table 1 ) we found that in tumour tissues the expression of c-myc (2.5-fold), hnRNP H (1.9-fold), and a-raf WT (1.3-fold) was significantly higher than in normal tissues. In contrast, a-raf short expression in tumours was significantly downregulated compared to normal tissues (1.6-fold decrease). Pearson's correlation (Fig. 6C) showed a significant correlation between c-myc/hnrnph (r p =0.8; p<0.001) and hnrnph/a-raf wt (r p =0.7; p<0.009).
Additionally, we assessed endogenous mRNA expression levels of c-myc and a-raf short in a series of 29 human Dukes B colon carcinomas and autologous adjacent non-malignant tissues by semi-quantitative RT-PCR (Fig. 6B , Table 1 ). Similar to the results observed in head and neck carcinomas, at the single-patient level a median relative overexpression of 6.4-fold for c-myc and 0.85-fold for a-raf short was observed in tumour specimens. Furthermore, comparing the relative expression in normal and tumour tissues, c-myc expression was significantly higher in tumours than in normal tissue. In contrast, a-raf short expression was significantly downregulated in tumours compared to normal. Importantly, we observe similar trends in the corresponding A-Raf protein isoform levels, in a limited number of autologous tissue samples from head and neck carcinomas (n=3). While ARaf short protein is downregulated in carcinomas by trend (p=0.08), expression of A-Raf wt prevails in carcinomas (p=0.02) (Fig. S6 ).
The other two human A-Raf isoforms, daRaf1 and daRaf2, were found to be barely detectable at the mRNA level in the human tissues investigated (semi-quantitative RT-PCR, 1/89 samples, data not shown). Expression of these isoforms was only investigated in mouse tissues and their expression/regulation in human tissues is not known.
Discussion
Alternative splicing occurs in more than 90% of genes (36) , and is considered as a key regulatory process by which a common pre-mRNA transcript leads to different mature RNAs, thus producing diverse and even antagonistic functions (37) . This greatly expands information content and versatility of the transcriptome generating tissue, stage, and development specific gene expression patterns (38) . Tumour suppressors are often inactivated by splicing in cancer, whereas oncogenes are inactivated by alternative splicing during normal differentiation (39, 40) . Components of the splicing machinery, such as hnRNP proteins and other RNA binding proteins, have been found altered in tumours and can contribute to cancer cell survival and invasiveness (41) .
We showed previously that the splicing factor hnRNP H is overexpressed in colon and head and neck cancers, and promotes the correct splicing of the a-raf mRNA that encodes the wildtype full-length A-Raf protein, which binds to and inhibits the pro-apoptotic kinase MST2 (6) . In this previous work we also showed that overexpression of A-Raf WT can overcome the effects of siRNA-mediated knockdown of hnRNP H. hnRNP H can regulate alternative splicing of Bcl-X (42) and a neuron-specific variant of Src (43) . In both cases, hnRNP H binds to G-rich RNA stretches (44) , similar to sequences found in the intron sequences included in A-Raf short . Although hnRNP H favours the production of the proapoptotic Bcl-X s isoform (42) , this splicing event does not prevent the A-Raf mediated rescue from apoptosis resulting from hnRNP H overexpression (6).
A-Raf short differs from DA-Raf1 and 2, which encompasses the uninterrupted RBD and adjacent cysteine rich domain. DA-Raf1 and 2 were not expressed in head and neck tissues and in human colon specimens except for one out of 89 samples (data not shown). This fits the current understanding of alternative splicing as usually only two isoforms of a given number of potential isoforms are predominant at the same time in a given tissue (36) . Intron inclusion is a rare event in alternative splicing (36) and, in combination with pre-terminal stop codons, these transcripts are commonly prone to nonsense-mediated decay (32) . However, sequence-specific Northern blotting showed that a-raf short mRNA exists in normal human tissues such as brain, placenta, kidney, pancreas, lung, and spleen (data not shown). The resulting A-Raf short protein is expressed both in cultured cells and in human tissues at low but stable levels, which is consistent with recent findings that such pre-terminated mRNAs typically express low levels of protein (45) .
Functionally, A-Raf short inhibits ERK pathway activation by competing for binding to activated Ras. This was un-expected, as intron 2 is inserted into the RBD between glutamine 29 (66 in Raf-1) and lysine 47 (84 in Raf-1), which together with arginine 52 (89 in Raf-1) form a functional epitope in Raf-1 that determines the affinity to Ras (46) . However, the binding of A-Raf short to Ras was GTP dependent and of similar affinity as full-length A-Raf, suggesting a functionally relevant interaction. The functionality of this interaction was corroborated by the finding that A-Raf short behaved as a dominant negative mutant, which suppressed Ras mediated transformation and ERK activation. In contrast, A-Raf short cannot bind to and inhibit MST2 pro-apoptotic signalling. Our finding that the expression of ARaf short is reduced in cancers correlating with the overexpression of hnRNP H and increased expression of full-length A-Raf protein also suggest that alternative a-raf splicing is a pathophysiological mechanism that tumours use to evade apoptosis.
We show that one mechanism regulating hnRNP H levels is via the proto-oncogene c-Myc. As suggested by data from the ENCODE project (31) we show that c-Myc binds directly to a non-canonical E-box in the hnRNP H1 gene promoter in a mitogen-dependent way. Knockdown of c-Myc decreased levels of hnRNP H and subsequent A-Raf short splice form selection. Activation of c-Myc had the opposite effect. Interestingly, c-Myc also stimulates the expression of other members of the hnRNP family, hnRNP A1, hnRNP A2, and hnRNP I (47). These hnRNP proteins promote the alternative splicing of pyruvate kinase resulting in the expression of the embryonic isoform, PKM2, which is almost universally re-expressed in cancer, and stimulates aerobic glycolysis (48) . Thus, c-Myc can regulate two splice events via hnRNP proteins that enhance survival via A-Raf mediated MST2 inhibition and switch metabolism to the aerobic glycolysis typical for cancer cells. Additional crosstalk between these two pathways may exist at the protein level as A-Raf was reported to bind to and regulate PKM2 function (49) .
In summary, we propose the following working hypothesis (Fig. 6D) : In tumour cells high levels of c-Myc elevate expression of the splice factor hnRNP H shifting the balance of a-raf mRNA splicing in favour of producing the full-length A-Raf protein, which is crucial to keep pro-apoptotic MST2 signalling in check. In normal cells c-Myc levels are low, resulting in reduced hnRNP H expression and a shift of a-raf splicing towards A-Raf short with the dual effect of relieving repression of MST2 and reducing ERK pathway activity due to Ras blockade by A-Raf short .
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. (A) Flag-tagged A-Raf short or A-Raf WT were transfected in HeLa cells. Cells were serumstarved for 16 hours (0.1% FCS) or serum-stimulated (10% FCS) for 5min after starvation as indicated. A-Raf isoforms were immunoprecipitated with flag-tag specific antibodies, and analysed by immunoblotting for the interaction with Ras. (B) Endogenous Ras was immunoprecipitated from lysates of HeLa cells, which had been serum starved (0.1% FCS, 16 hours) or treated with full medium (10% FCS) after serum-starvation using a specifc antibody for Ras, and analysed by immunoblotting (upper panel). As an isotype control, an antibody specific for GFP was used (middle panel, 'Isotype'). Lysates were immunoblotted 
